| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 213 | 2026 | 946 | 22.670 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 174 | 2026 | 744 | 22.600 |
Why?
|
| Cardiovascular Diseases | 212 | 2026 | 2088 | 21.430 |
Why?
|
| Cholesterol, LDL | 197 | 2026 | 612 | 19.930 |
Why?
|
| Anticholesteremic Agents | 110 | 2026 | 241 | 17.530 |
Why?
|
| Hypercholesterolemia | 78 | 2026 | 234 | 15.670 |
Why?
|
| Troponin T | 86 | 2025 | 255 | 11.310 |
Why?
|
| Hypertriglyceridemia | 46 | 2026 | 118 | 10.010 |
Why?
|
| Triglycerides | 99 | 2026 | 605 | 9.350 |
Why?
|
| Coronary Disease | 92 | 2024 | 638 | 9.230 |
Why?
|
| Hyperlipoproteinemia Type II | 40 | 2026 | 121 | 9.180 |
Why?
|
| Lipoprotein(a) | 44 | 2026 | 140 | 9.060 |
Why?
|
| Hypolipidemic Agents | 53 | 2025 | 194 | 8.790 |
Why?
|
| Natriuretic Peptide, Brain | 69 | 2026 | 326 | 8.700 |
Why?
|
| Dyslipidemias | 45 | 2025 | 247 | 8.330 |
Why?
|
| Biomarkers | 222 | 2026 | 3415 | 7.290 |
Why?
|
| Coronary Artery Disease | 89 | 2025 | 870 | 7.190 |
Why?
|
| Heart Failure | 88 | 2026 | 2315 | 7.150 |
Why?
|
| Peptide Fragments | 64 | 2026 | 782 | 6.820 |
Why?
|
| Cholesterol, HDL | 87 | 2025 | 394 | 6.800 |
Why?
|
| Eicosapentaenoic Acid | 41 | 2025 | 82 | 6.630 |
Why?
|
| Cholesterol | 60 | 2026 | 541 | 6.390 |
Why?
|
| Risk Factors | 336 | 2026 | 10998 | 6.140 |
Why?
|
| Middle Aged | 554 | 2026 | 28911 | 6.110 |
Why?
|
| C-Reactive Protein | 72 | 2025 | 459 | 6.100 |
Why?
|
| Hyperlipidemias | 33 | 2026 | 189 | 5.950 |
Why?
|
| Ezetimibe | 44 | 2025 | 94 | 5.640 |
Why?
|
| Lipids | 69 | 2025 | 567 | 5.550 |
Why?
|
| Fatty Acids | 24 | 2025 | 377 | 5.530 |
Why?
|
| Aged | 385 | 2026 | 21279 | 5.370 |
Why?
|
| Dicarboxylic Acids | 19 | 2025 | 37 | 5.310 |
Why?
|
| Humans | 928 | 2026 | 131967 | 5.300 |
Why?
|
| Risk Assessment | 129 | 2026 | 3708 | 5.260 |
Why?
|
| Male | 645 | 2026 | 65357 | 4.830 |
Why?
|
| Stroke | 47 | 2024 | 1049 | 4.760 |
Why?
|
| Apolipoprotein C-III | 18 | 2025 | 46 | 4.720 |
Why?
|
| Myocardial Infarction | 45 | 2025 | 1002 | 4.690 |
Why?
|
| Lipoproteins | 27 | 2025 | 183 | 4.640 |
Why?
|
| Double-Blind Method | 102 | 2026 | 1638 | 4.550 |
Why?
|
| Female | 624 | 2026 | 71316 | 4.450 |
Why?
|
| Cardiology | 26 | 2023 | 507 | 4.000 |
Why?
|
| Diabetes Mellitus | 55 | 2026 | 893 | 3.990 |
Why?
|
| Plaque, Atherosclerotic | 28 | 2025 | 146 | 3.970 |
Why?
|
| Proprotein Convertase 9 | 33 | 2026 | 110 | 3.950 |
Why?
|
| Obesity | 50 | 2025 | 2392 | 3.820 |
Why?
|
| Metabolic Syndrome | 32 | 2025 | 363 | 3.810 |
Why?
|
| Atrial Fibrillation | 21 | 2024 | 734 | 3.590 |
Why?
|
| Fluorobenzenes | 25 | 2014 | 39 | 3.550 |
Why?
|
| Inflammation | 48 | 2024 | 1500 | 3.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 54 | 2025 | 1413 | 3.430 |
Why?
|
| United States | 201 | 2026 | 11827 | 3.410 |
Why?
|
| Apolipoproteins B | 32 | 2026 | 144 | 3.340 |
Why?
|
| Simvastatin | 30 | 2018 | 75 | 3.320 |
Why?
|
| Carotid Artery Diseases | 21 | 2018 | 132 | 3.290 |
Why?
|
| Incidence | 117 | 2026 | 3352 | 3.260 |
Why?
|
| Prospective Studies | 151 | 2026 | 6522 | 3.180 |
Why?
|
| Sulfonamides | 25 | 2014 | 296 | 3.050 |
Why?
|
| Hyperlipoproteinemia Type I | 7 | 2026 | 11 | 2.910 |
Why?
|
| Drug Therapy, Combination | 54 | 2025 | 1173 | 2.850 |
Why?
|
| Pyrimidines | 26 | 2025 | 445 | 2.850 |
Why?
|
| Heptanoic Acids | 32 | 2014 | 78 | 2.680 |
Why?
|
| Brain Ischemia | 13 | 2023 | 261 | 2.670 |
Why?
|
| Troponin I | 15 | 2026 | 123 | 2.650 |
Why?
|
| Peripheral Arterial Disease | 24 | 2023 | 315 | 2.610 |
Why?
|
| Pyrroles | 33 | 2015 | 187 | 2.570 |
Why?
|
| Treatment Outcome | 126 | 2026 | 13011 | 2.470 |
Why?
|
| Acute Coronary Syndrome | 16 | 2024 | 246 | 2.430 |
Why?
|
| Azetidines | 24 | 2014 | 63 | 2.420 |
Why?
|
| Monocytes | 16 | 2025 | 337 | 2.360 |
Why?
|
| American Heart Association | 17 | 2021 | 321 | 2.320 |
Why?
|
| Fenofibrate | 12 | 2014 | 59 | 2.300 |
Why?
|
| Adult | 193 | 2026 | 31734 | 2.290 |
Why?
|
| Fatty Acids, Omega-3 | 11 | 2023 | 81 | 2.240 |
Why?
|
| Cholesterol Ester Transfer Proteins | 17 | 2026 | 39 | 2.230 |
Why?
|
| Life Style | 17 | 2024 | 445 | 2.200 |
Why?
|
| Serine Proteinase Inhibitors | 6 | 2026 | 39 | 2.200 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 21 | 2022 | 89 | 2.190 |
Why?
|
| Hypertension | 40 | 2026 | 1362 | 2.190 |
Why?
|
| Practice Guidelines as Topic | 34 | 2025 | 1307 | 2.190 |
Why?
|
| Blood Proteins | 16 | 2026 | 140 | 2.120 |
Why?
|
| Proteomics | 20 | 2026 | 614 | 2.070 |
Why?
|
| Polymorphism, Single Nucleotide | 50 | 2025 | 2863 | 2.070 |
Why?
|
| RNA, Small Interfering | 7 | 2025 | 664 | 2.070 |
Why?
|
| Prognosis | 75 | 2025 | 4961 | 2.060 |
Why?
|
| Follow-Up Studies | 94 | 2025 | 5298 | 2.020 |
Why?
|
| Platelet Aggregation Inhibitors | 19 | 2025 | 274 | 2.010 |
Why?
|
| Proprotein Convertases | 11 | 2023 | 25 | 1.990 |
Why?
|
| Time Factors | 80 | 2024 | 6285 | 1.960 |
Why?
|
| Adipose Tissue | 13 | 2020 | 495 | 1.910 |
Why?
|
| Carotid Intima-Media Thickness | 16 | 2023 | 79 | 1.880 |
Why?
|
| Galectin 3 | 8 | 2024 | 31 | 1.830 |
Why?
|
| Antibodies, Monoclonal | 23 | 2026 | 1012 | 1.830 |
Why?
|
| Indoles | 22 | 2011 | 205 | 1.830 |
Why?
|
| Blood Pressure | 32 | 2024 | 1345 | 1.780 |
Why?
|
| Cohort Studies | 88 | 2026 | 5122 | 1.780 |
Why?
|
| Myocardial Ischemia | 17 | 2025 | 310 | 1.760 |
Why?
|
| Lipid Metabolism | 10 | 2025 | 372 | 1.680 |
Why?
|
| Aged, 80 and over | 70 | 2025 | 6922 | 1.670 |
Why?
|
| Proportional Hazards Models | 49 | 2026 | 1406 | 1.670 |
Why?
|
| Niacin | 15 | 2016 | 59 | 1.660 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2025 | 1626 | 1.660 |
Why?
|
| Coronary Artery Bypass | 16 | 2021 | 517 | 1.650 |
Why?
|
| Lipoproteins, LDL | 19 | 2021 | 118 | 1.620 |
Why?
|
| Insulin Resistance | 19 | 2021 | 683 | 1.610 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2026 | 777 | 1.540 |
Why?
|
| Lipoproteins, HDL | 15 | 2024 | 97 | 1.530 |
Why?
|
| Weight Loss | 19 | 2017 | 530 | 1.510 |
Why?
|
| Intercellular Adhesion Molecule-1 | 27 | 2023 | 122 | 1.500 |
Why?
|
| Genome-Wide Association Study | 35 | 2025 | 1840 | 1.500 |
Why?
|
| Primary Prevention | 15 | 2025 | 175 | 1.490 |
Why?
|
| Renal Insufficiency, Chronic | 18 | 2025 | 850 | 1.490 |
Why?
|
| Carotid Arteries | 12 | 2018 | 126 | 1.470 |
Why?
|
| Oxazolidinones | 4 | 2017 | 32 | 1.470 |
Why?
|
| RNAi Therapeutics | 4 | 2025 | 17 | 1.450 |
Why?
|
| Vascular Calcification | 8 | 2024 | 70 | 1.380 |
Why?
|
| Inflammation Mediators | 14 | 2020 | 228 | 1.370 |
Why?
|
| Receptors, LDL | 11 | 2026 | 106 | 1.320 |
Why?
|
| Rosuvastatin Calcium | 28 | 2021 | 42 | 1.300 |
Why?
|
| Hospitalization | 16 | 2021 | 1942 | 1.280 |
Why?
|
| Dioxygenases | 7 | 2025 | 72 | 1.270 |
Why?
|
| Pancreatitis | 4 | 2025 | 142 | 1.260 |
Why?
|
| Apolipoprotein A-I | 17 | 2018 | 80 | 1.240 |
Why?
|
| Fatty Acids, Monounsaturated | 18 | 2009 | 50 | 1.230 |
Why?
|
| CD11c Antigen | 8 | 2021 | 40 | 1.210 |
Why?
|
| Venous Thromboembolism | 5 | 2025 | 180 | 1.210 |
Why?
|
| Prevalence | 36 | 2025 | 2697 | 1.200 |
Why?
|
| Serine Endopeptidases | 11 | 2023 | 199 | 1.190 |
Why?
|
| Risk Reduction Behavior | 13 | 2021 | 148 | 1.190 |
Why?
|
| Nutrition Surveys | 10 | 2025 | 327 | 1.180 |
Why?
|
| Blood Glucose | 35 | 2021 | 1104 | 1.180 |
Why?
|
| Predictive Value of Tests | 40 | 2025 | 2308 | 1.170 |
Why?
|
| Heart Diseases | 8 | 2022 | 505 | 1.160 |
Why?
|
| Exercise | 15 | 2022 | 866 | 1.140 |
Why?
|
| Genetic Testing | 7 | 2026 | 1101 | 1.140 |
Why?
|
| Body Mass Index | 37 | 2025 | 1695 | 1.110 |
Why?
|
| Cause of Death | 13 | 2025 | 512 | 1.100 |
Why?
|
| Galectins | 7 | 2024 | 23 | 1.090 |
Why?
|
| Adiponectin | 12 | 2025 | 124 | 1.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 7 | 2019 | 110 | 1.070 |
Why?
|
| Cross-Sectional Studies | 55 | 2025 | 3843 | 1.070 |
Why?
|
| Muscle, Skeletal | 9 | 2023 | 1004 | 1.070 |
Why?
|
| Secondary Prevention | 9 | 2022 | 220 | 1.070 |
Why?
|
| Carotid Artery, Common | 4 | 2011 | 60 | 1.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2023 | 580 | 1.050 |
Why?
|
| Arteriosclerosis | 14 | 2007 | 110 | 1.040 |
Why?
|
| Diabetes Complications | 7 | 2020 | 199 | 1.040 |
Why?
|
| Longitudinal Studies | 27 | 2025 | 1519 | 1.030 |
Why?
|
| Homozygote | 7 | 2025 | 549 | 1.020 |
Why?
|
| Polymorphism, Genetic | 18 | 2019 | 795 | 1.010 |
Why?
|
| Sulfhydryl Compounds | 9 | 2020 | 56 | 1.010 |
Why?
|
| Muscular Diseases | 5 | 2022 | 124 | 1.010 |
Why?
|
| Genetic Variation | 15 | 2023 | 1566 | 1.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2020 | 22 | 0.980 |
Why?
|
| Apolipoproteins E | 16 | 2021 | 188 | 0.970 |
Why?
|
| Apolipoproteins A | 6 | 2014 | 53 | 0.970 |
Why?
|
| Macrophage-1 Antigen | 14 | 2014 | 22 | 0.960 |
Why?
|
| Foam Cells | 3 | 2025 | 21 | 0.950 |
Why?
|
| Registries | 21 | 2024 | 1598 | 0.950 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 12 | 2010 | 72 | 0.940 |
Why?
|
| Genetic Loci | 14 | 2025 | 359 | 0.940 |
Why?
|
| Healthcare Disparities | 7 | 2021 | 502 | 0.930 |
Why?
|
| Residence Characteristics | 15 | 2021 | 293 | 0.930 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 460 | 0.920 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2025 | 602 | 0.920 |
Why?
|
| Myocardial Revascularization | 8 | 2024 | 100 | 0.920 |
Why?
|
| Smoking | 20 | 2026 | 928 | 0.920 |
Why?
|
| Repressor Proteins | 6 | 2025 | 781 | 0.890 |
Why?
|
| Animals | 93 | 2026 | 34460 | 0.890 |
Why?
|
| Diabetic Angiopathies | 8 | 2020 | 67 | 0.890 |
Why?
|
| Societies, Medical | 7 | 2025 | 798 | 0.880 |
Why?
|
| Dietary Supplements | 5 | 2024 | 454 | 0.880 |
Why?
|
| Interleukin-6 | 13 | 2024 | 419 | 0.870 |
Why?
|
| Lipoprotein Lipase | 11 | 2025 | 62 | 0.870 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 13 | 2008 | 29 | 0.870 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2025 | 1255 | 0.870 |
Why?
|
| Postprandial Period | 5 | 2025 | 86 | 0.870 |
Why?
|
| Myositis | 3 | 2017 | 106 | 0.870 |
Why?
|
| Prediabetic State | 8 | 2026 | 66 | 0.860 |
Why?
|
| Up-Regulation | 14 | 2020 | 832 | 0.850 |
Why?
|
| Myocardium | 22 | 2020 | 876 | 0.840 |
Why?
|
| Risk | 23 | 2021 | 739 | 0.840 |
Why?
|
| Hyperglycemia | 8 | 2025 | 234 | 0.830 |
Why?
|
| Magnetic Resonance Imaging | 24 | 2023 | 3928 | 0.820 |
Why?
|
| DNA-Binding Proteins | 9 | 2025 | 1964 | 0.820 |
Why?
|
| Coronary Vessels | 16 | 2024 | 529 | 0.820 |
Why?
|
| Chemokine CCL2 | 9 | 2021 | 114 | 0.810 |
Why?
|
| Odds Ratio | 24 | 2023 | 1236 | 0.800 |
Why?
|
| Intra-Abdominal Fat | 2 | 2017 | 64 | 0.800 |
Why?
|
| Cognition Disorders | 4 | 2021 | 565 | 0.800 |
Why?
|
| Ageism | 1 | 2023 | 4 | 0.790 |
Why?
|
| Age Factors | 27 | 2025 | 2869 | 0.790 |
Why?
|
| Stroke Volume | 14 | 2025 | 532 | 0.780 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2024 | 50 | 0.780 |
Why?
|
| Computer Simulation | 2 | 2025 | 681 | 0.770 |
Why?
|
| Cardiomyopathies | 9 | 2019 | 518 | 0.770 |
Why?
|
| Oligonucleotides | 4 | 2025 | 96 | 0.760 |
Why?
|
| Mortality | 6 | 2020 | 261 | 0.750 |
Why?
|
| Carotid Artery, Internal | 3 | 2015 | 56 | 0.750 |
Why?
|
| Young Adult | 35 | 2025 | 10108 | 0.750 |
Why?
|
| Linear Models | 16 | 2017 | 695 | 0.730 |
Why?
|
| Glomerular Filtration Rate | 17 | 2025 | 568 | 0.730 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2021 | 910 | 0.730 |
Why?
|
| Genetic Predisposition to Disease | 36 | 2025 | 3425 | 0.720 |
Why?
|
| Genotype | 42 | 2023 | 2655 | 0.720 |
Why?
|
| Drug Costs | 2 | 2019 | 62 | 0.710 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 496 | 0.710 |
Why?
|
| Heterozygote | 8 | 2026 | 728 | 0.710 |
Why?
|
| Sex Factors | 27 | 2024 | 1352 | 0.710 |
Why?
|
| Hypoglycemic Agents | 6 | 2022 | 475 | 0.710 |
Why?
|
| Dementia | 4 | 2024 | 435 | 0.700 |
Why?
|
| Fish Oils | 2 | 2021 | 82 | 0.700 |
Why?
|
| Mice, Inbred C57BL | 34 | 2025 | 4762 | 0.700 |
Why?
|
| Football | 5 | 2014 | 36 | 0.700 |
Why?
|
| Drug Tolerance | 2 | 2021 | 40 | 0.690 |
Why?
|
| Neutrophils | 16 | 2023 | 369 | 0.690 |
Why?
|
| Mice | 64 | 2025 | 18504 | 0.670 |
Why?
|
| Proteome | 6 | 2025 | 288 | 0.670 |
Why?
|
| Cell Adhesion Molecules | 12 | 2005 | 227 | 0.670 |
Why?
|
| Mice, Knockout | 32 | 2025 | 3864 | 0.670 |
Why?
|
| CD18 Antigens | 12 | 2017 | 43 | 0.660 |
Why?
|
| Eligibility Determination | 2 | 2019 | 36 | 0.660 |
Why?
|
| Disease Progression | 29 | 2024 | 2226 | 0.650 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 3 | 2019 | 8 | 0.650 |
Why?
|
| Calcinosis | 7 | 2024 | 187 | 0.650 |
Why?
|
| Echocardiography | 11 | 2025 | 1138 | 0.640 |
Why?
|
| Endothelium, Vascular | 14 | 2021 | 471 | 0.640 |
Why?
|
| Hematologic Neoplasms | 2 | 2026 | 315 | 0.640 |
Why?
|
| Testosterone | 6 | 2024 | 604 | 0.630 |
Why?
|
| Phenotype | 25 | 2025 | 4531 | 0.630 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2021 | 713 | 0.630 |
Why?
|
| Global Health | 5 | 2025 | 633 | 0.620 |
Why?
|
| Lipoproteins, VLDL | 4 | 2018 | 53 | 0.620 |
Why?
|
| Population Surveillance | 6 | 2021 | 397 | 0.610 |
Why?
|
| Retirement | 4 | 2014 | 18 | 0.610 |
Why?
|
| Drug Monitoring | 9 | 2021 | 286 | 0.610 |
Why?
|
| Administration, Oral | 5 | 2026 | 710 | 0.610 |
Why?
|
| Chemokine CCL5 | 3 | 2013 | 53 | 0.610 |
Why?
|
| Comorbidity | 16 | 2024 | 1607 | 0.600 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 28 | 0.600 |
Why?
|
| Logistic Models | 21 | 2020 | 1838 | 0.600 |
Why?
|
| Clinical Trials as Topic | 13 | 2020 | 1141 | 0.600 |
Why?
|
| Carotid Stenosis | 4 | 2021 | 107 | 0.590 |
Why?
|
| Heart Transplantation | 12 | 2005 | 833 | 0.590 |
Why?
|
| Tunica Intima | 9 | 2014 | 61 | 0.590 |
Why?
|
| Ischemia | 7 | 2022 | 355 | 0.590 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 741 | 0.590 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2017 | 104 | 0.590 |
Why?
|
| Ventricular Remodeling | 5 | 2025 | 155 | 0.580 |
Why?
|
| Ventricular Function, Left | 9 | 2025 | 542 | 0.580 |
Why?
|
| Particle Size | 7 | 2025 | 137 | 0.580 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 140 | 0.580 |
Why?
|
| Guideline Adherence | 13 | 2019 | 393 | 0.570 |
Why?
|
| Angiopoietin-like Proteins | 4 | 2026 | 15 | 0.570 |
Why?
|
| Preventive Health Services | 2 | 2021 | 58 | 0.570 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2022 | 109 | 0.570 |
Why?
|
| Veterans Health | 6 | 2020 | 171 | 0.560 |
Why?
|
| Disease Management | 5 | 2019 | 565 | 0.560 |
Why?
|
| Pravastatin | 5 | 2012 | 22 | 0.550 |
Why?
|
| Aspirin | 8 | 2020 | 216 | 0.550 |
Why?
|
| Vitamin D | 2 | 2017 | 194 | 0.550 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 74 | 0.540 |
Why?
|
| Protein Precursors | 5 | 2021 | 147 | 0.540 |
Why?
|
| Cytokines | 5 | 2020 | 1354 | 0.540 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 125 | 0.540 |
Why?
|
| Esters | 11 | 2025 | 33 | 0.540 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 721 | 0.540 |
Why?
|
| Energy Metabolism | 2 | 2024 | 786 | 0.540 |
Why?
|
| Deoxyglucose | 4 | 2020 | 42 | 0.530 |
Why?
|
| Coronary Angiography | 15 | 2025 | 457 | 0.530 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 1790 | 0.530 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 5 | 2025 | 156 | 0.530 |
Why?
|
| Renal Insufficiency | 3 | 2011 | 252 | 0.530 |
Why?
|
| Lactic Acid | 6 | 2014 | 148 | 0.520 |
Why?
|
| Nurse Practitioners | 4 | 2021 | 50 | 0.520 |
Why?
|
| Receptors, Immunologic | 6 | 2014 | 126 | 0.520 |
Why?
|
| Severity of Illness Index | 25 | 2021 | 3095 | 0.520 |
Why?
|
| Cell Adhesion | 17 | 2010 | 312 | 0.520 |
Why?
|
| Alcohol Drinking | 8 | 2019 | 347 | 0.510 |
Why?
|
| Physician Assistants | 4 | 2021 | 80 | 0.510 |
Why?
|
| Antihypertensive Agents | 8 | 2024 | 422 | 0.510 |
Why?
|
| Sensitivity and Specificity | 21 | 2025 | 2148 | 0.500 |
Why?
|
| Apolipoproteins | 9 | 2023 | 70 | 0.500 |
Why?
|
| Genetic Markers | 5 | 2015 | 605 | 0.500 |
Why?
|
| P-Selectin | 9 | 2011 | 69 | 0.490 |
Why?
|
| Postmenopause | 6 | 2022 | 149 | 0.490 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2013 | 440 | 0.490 |
Why?
|
| Ultrasonography, Interventional | 9 | 2018 | 206 | 0.490 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 199 | 0.490 |
Why?
|
| Ultrasonography | 15 | 2018 | 976 | 0.490 |
Why?
|
| Drug Prescriptions | 7 | 2020 | 230 | 0.480 |
Why?
|
| Down-Regulation | 8 | 2021 | 659 | 0.480 |
Why?
|
| Glucose Intolerance | 4 | 2021 | 78 | 0.480 |
Why?
|
| Phospholipases A | 3 | 2006 | 30 | 0.480 |
Why?
|
| Veterans | 8 | 2023 | 1801 | 0.470 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2025 | 73 | 0.470 |
Why?
|
| Leukocytes | 6 | 2014 | 211 | 0.470 |
Why?
|
| Consensus | 7 | 2025 | 530 | 0.470 |
Why?
|
| RNA, Messenger | 19 | 2025 | 2573 | 0.460 |
Why?
|
| Leg | 6 | 2023 | 124 | 0.460 |
Why?
|
| Adolescent | 31 | 2026 | 21008 | 0.460 |
Why?
|
| Calcium | 9 | 2022 | 1043 | 0.460 |
Why?
|
| Myocardial Reperfusion Injury | 7 | 2019 | 127 | 0.460 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 85 | 0.460 |
Why?
|
| Patient Selection | 6 | 2019 | 726 | 0.460 |
Why?
|
| Medication Adherence | 6 | 2021 | 334 | 0.460 |
Why?
|
| Troponin | 5 | 2024 | 70 | 0.460 |
Why?
|
| Promoter Regions, Genetic | 4 | 2017 | 1219 | 0.450 |
Why?
|
| Cell Movement | 8 | 2017 | 886 | 0.450 |
Why?
|
| Enzyme Inhibitors | 4 | 2017 | 566 | 0.450 |
Why?
|
| Dietary Fats | 7 | 2015 | 276 | 0.450 |
Why?
|
| Clinical Decision-Making | 5 | 2022 | 313 | 0.440 |
Why?
|
| Endothelial Cells | 4 | 2021 | 531 | 0.440 |
Why?
|
| Liver | 17 | 2025 | 1802 | 0.440 |
Why?
|
| Amides | 9 | 2020 | 91 | 0.440 |
Why?
|
| Surveys and Questionnaires | 11 | 2022 | 4058 | 0.430 |
Why?
|
| Interleukins | 2 | 2014 | 121 | 0.430 |
Why?
|
| RNA Interference | 4 | 2023 | 495 | 0.430 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 90 | 0.430 |
Why?
|
| Texas | 15 | 2024 | 3629 | 0.430 |
Why?
|
| Asymptomatic Diseases | 8 | 2020 | 78 | 0.430 |
Why?
|
| E-Selectin | 8 | 2011 | 39 | 0.420 |
Why?
|
| Mass Screening | 9 | 2024 | 825 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 1078 | 0.420 |
Why?
|
| Retrospective Studies | 39 | 2024 | 17703 | 0.410 |
Why?
|
| Goals | 2 | 2011 | 125 | 0.410 |
Why?
|
| Lymphopenia | 1 | 2014 | 34 | 0.410 |
Why?
|
| Physicians | 5 | 2023 | 634 | 0.410 |
Why?
|
| Angina, Unstable | 6 | 2021 | 49 | 0.410 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.410 |
Why?
|
| Albuminuria | 8 | 2025 | 106 | 0.400 |
Why?
|
| Aging | 9 | 2024 | 1269 | 0.400 |
Why?
|
| Gene Frequency | 11 | 2019 | 750 | 0.400 |
Why?
|
| Vascular Stiffness | 5 | 2025 | 83 | 0.400 |
Why?
|
| Genetic Association Studies | 6 | 2021 | 835 | 0.390 |
Why?
|
| Brain Infarction | 1 | 2013 | 28 | 0.390 |
Why?
|
| Natriuretic Peptides | 2 | 2025 | 9 | 0.390 |
Why?
|
| Femoral Artery | 5 | 2023 | 136 | 0.390 |
Why?
|
| Cost-Benefit Analysis | 5 | 2025 | 544 | 0.390 |
Why?
|
| Reproducibility of Results | 20 | 2022 | 2992 | 0.390 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 63 | 0.380 |
Why?
|
| Macrophages | 7 | 2024 | 663 | 0.380 |
Why?
|
| Leptin | 5 | 2025 | 219 | 0.380 |
Why?
|
| Mutation | 17 | 2025 | 6200 | 0.380 |
Why?
|
| Case-Control Studies | 21 | 2022 | 3453 | 0.370 |
Why?
|
| Health Care Costs | 3 | 2025 | 400 | 0.370 |
Why?
|
| Adipocytes | 4 | 2025 | 173 | 0.370 |
Why?
|
| Flushing | 3 | 2010 | 6 | 0.370 |
Why?
|
| CD11b Antigen | 4 | 2009 | 35 | 0.370 |
Why?
|
| Diet, High-Fat | 6 | 2025 | 264 | 0.370 |
Why?
|
| CD36 Antigens | 5 | 2022 | 35 | 0.360 |
Why?
|
| Heart Valves | 2 | 2010 | 52 | 0.360 |
Why?
|
| CD11 Antigens | 3 | 2017 | 11 | 0.360 |
Why?
|
| Fibrinogen | 7 | 2023 | 166 | 0.360 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 304 | 0.360 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 108 | 0.360 |
Why?
|
| Alzheimer Disease | 3 | 2026 | 876 | 0.350 |
Why?
|
| Alleles | 12 | 2024 | 1713 | 0.350 |
Why?
|
| Sphingolipids | 1 | 2011 | 35 | 0.350 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2011 | 85 | 0.350 |
Why?
|
| DNA | 5 | 2013 | 1440 | 0.350 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2022 | 293 | 0.350 |
Why?
|
| Integrin alpha Chains | 2 | 2017 | 15 | 0.350 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2011 | 74 | 0.350 |
Why?
|
| Multivariate Analysis | 12 | 2021 | 1406 | 0.350 |
Why?
|
| Coronary Stenosis | 2 | 2011 | 77 | 0.340 |
Why?
|
| Tobacco Products | 2 | 2023 | 61 | 0.340 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2015 | 237 | 0.340 |
Why?
|
| Exome | 5 | 2021 | 1076 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 55 | 0.340 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 681 | 0.340 |
Why?
|
| Kidney | 8 | 2023 | 1304 | 0.340 |
Why?
|
| Intermittent Claudication | 4 | 2023 | 49 | 0.330 |
Why?
|
| Metabolomics | 3 | 2025 | 493 | 0.330 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 162 | 0.330 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2023 | 25 | 0.320 |
Why?
|
| Postoperative Complications | 10 | 2013 | 3135 | 0.320 |
Why?
|
| Europe | 8 | 2018 | 373 | 0.320 |
Why?
|
| Lovastatin | 7 | 2010 | 26 | 0.320 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 1173 | 0.320 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2021 | 34 | 0.320 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2023 | 94 | 0.320 |
Why?
|
| Survival Rate | 12 | 2024 | 2154 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2024 | 379 | 0.310 |
Why?
|
| Menopause | 2 | 2022 | 87 | 0.310 |
Why?
|
| Acute Disease | 6 | 2024 | 1153 | 0.310 |
Why?
|
| Preoperative Care | 3 | 2012 | 357 | 0.310 |
Why?
|
| Diet | 7 | 2013 | 1118 | 0.310 |
Why?
|
| Interleukin-1beta | 3 | 2022 | 159 | 0.310 |
Why?
|
| Hematopoiesis | 5 | 2024 | 220 | 0.310 |
Why?
|
| Sleep | 2 | 2025 | 373 | 0.310 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2010 | 39 | 0.300 |
Why?
|
| Forecasting | 4 | 2021 | 361 | 0.300 |
Why?
|
| Gene Expression Regulation | 10 | 2025 | 2357 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 5 | 2023 | 941 | 0.300 |
Why?
|
| Pharmacogenetics | 5 | 2024 | 203 | 0.300 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2025 | 550 | 0.290 |
Why?
|
| Glucose | 4 | 2025 | 850 | 0.290 |
Why?
|
| Delayed-Action Preparations | 8 | 2010 | 121 | 0.290 |
Why?
|
| Lipase | 6 | 2014 | 88 | 0.290 |
Why?
|
| Leukocyte Count | 7 | 2017 | 249 | 0.290 |
Why?
|
| Platelet Aggregation | 4 | 2011 | 104 | 0.290 |
Why?
|
| United Kingdom | 3 | 2025 | 255 | 0.290 |
Why?
|
| Platelet Activation | 4 | 2017 | 67 | 0.290 |
Why?
|
| Health Status Disparities | 3 | 2024 | 277 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2013 | 643 | 0.280 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 570 | 0.280 |
Why?
|
| Health Surveys | 3 | 2008 | 263 | 0.280 |
Why?
|
| Drug Combinations | 7 | 2025 | 280 | 0.280 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2021 | 359 | 0.280 |
Why?
|
| Cholestyramine Resin | 2 | 2004 | 13 | 0.280 |
Why?
|
| Th1 Cells | 3 | 2021 | 156 | 0.280 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 23 | 0.280 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 99 | 0.270 |
Why?
|
| Heart Arrest | 3 | 2024 | 380 | 0.270 |
Why?
|
| Quinazolines | 3 | 2016 | 181 | 0.270 |
Why?
|
| Homocysteine | 3 | 2022 | 118 | 0.270 |
Why?
|
| Ferritins | 2 | 2024 | 109 | 0.270 |
Why?
|
| Cells, Cultured | 15 | 2021 | 2963 | 0.270 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2018 | 293 | 0.270 |
Why?
|
| Sex Characteristics | 4 | 2022 | 338 | 0.270 |
Why?
|
| Injections, Subcutaneous | 5 | 2024 | 134 | 0.270 |
Why?
|
| Diet Therapy | 2 | 2021 | 41 | 0.270 |
Why?
|
| Lipid Regulating Agents | 3 | 2022 | 6 | 0.270 |
Why?
|
| Telemedicine | 2 | 2025 | 524 | 0.270 |
Why?
|
| Women's Health | 2 | 2020 | 143 | 0.270 |
Why?
|
| Professional Practice Gaps | 2 | 2018 | 14 | 0.260 |
Why?
|
| Ambulatory Care | 4 | 2018 | 407 | 0.260 |
Why?
|
| Overweight | 5 | 2025 | 378 | 0.260 |
Why?
|
| Acute Kidney Injury | 4 | 2024 | 690 | 0.260 |
Why?
|
| Community Health Workers | 2 | 2025 | 80 | 0.260 |
Why?
|
| Luteinizing Hormone | 2 | 2024 | 134 | 0.260 |
Why?
|
| Aza Compounds | 2 | 2026 | 13 | 0.260 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 355 | 0.260 |
Why?
|
| Adipose Tissue, White | 2 | 2025 | 95 | 0.260 |
Why?
|
| Dendritic Cells | 2 | 2021 | 437 | 0.250 |
Why?
|
| ROC Curve | 5 | 2018 | 622 | 0.250 |
Why?
|
| Pyrrolidines | 2 | 2026 | 47 | 0.250 |
Why?
|
| Kidney Diseases | 3 | 2021 | 482 | 0.250 |
Why?
|
| Haplotypes | 6 | 2012 | 550 | 0.250 |
Why?
|
| Dihydrotestosterone | 2 | 2024 | 72 | 0.250 |
Why?
|
| Adipokines | 2 | 2025 | 121 | 0.250 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 298 | 0.250 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 36 | 0.250 |
Why?
|
| Signal Transduction | 6 | 2021 | 4693 | 0.250 |
Why?
|
| Creatine Kinase | 3 | 2019 | 64 | 0.250 |
Why?
|
| Fructosamine | 3 | 2018 | 11 | 0.250 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 2013 | 60 | 0.250 |
Why?
|
| Heart Ventricles | 4 | 2021 | 770 | 0.250 |
Why?
|
| Triazoles | 3 | 2026 | 144 | 0.250 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 100 | 0.250 |
Why?
|
| Education, Medical, Continuing | 3 | 2016 | 134 | 0.250 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2023 | 88 | 0.240 |
Why?
|
| Insulin | 9 | 2021 | 1154 | 0.240 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 233 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2025 | 76 | 0.240 |
Why?
|
| Heart | 5 | 2016 | 676 | 0.240 |
Why?
|
| Health Behavior | 2 | 2008 | 390 | 0.240 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1076 | 0.240 |
Why?
|
| Gene-Environment Interaction | 2 | 2025 | 129 | 0.240 |
Why?
|
| Body Weight | 2 | 2009 | 990 | 0.240 |
Why?
|
| tau Proteins | 2 | 2026 | 257 | 0.240 |
Why?
|
| Cognition | 3 | 2024 | 845 | 0.240 |
Why?
|
| Chemokines, CC | 1 | 2005 | 26 | 0.240 |
Why?
|
| Flow Cytometry | 11 | 2020 | 772 | 0.240 |
Why?
|
| Lower Extremity | 3 | 2022 | 184 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2014 | 792 | 0.240 |
Why?
|
| Cystatin C | 4 | 2016 | 71 | 0.230 |
Why?
|
| Medical Laboratory Science | 1 | 2005 | 12 | 0.230 |
Why?
|
| Internet | 3 | 2024 | 423 | 0.230 |
Why?
|
| Quantitative Trait Loci | 4 | 2017 | 307 | 0.230 |
Why?
|
| Developed Countries | 1 | 2025 | 44 | 0.230 |
Why?
|
| Disease Models, Animal | 11 | 2019 | 4684 | 0.230 |
Why?
|
| Biological Transport | 3 | 2024 | 333 | 0.230 |
Why?
|
| Social Class | 2 | 2017 | 212 | 0.230 |
Why?
|
| Primary Health Care | 6 | 2021 | 791 | 0.230 |
Why?
|
| Air Pollution | 1 | 2026 | 78 | 0.230 |
Why?
|
| Carrier Proteins | 4 | 2024 | 1025 | 0.230 |
Why?
|
| Body Temperature Regulation | 1 | 2025 | 51 | 0.230 |
Why?
|
| White Matter | 2 | 2018 | 231 | 0.220 |
Why?
|
| Aspartic Acid | 1 | 2025 | 83 | 0.220 |
Why?
|
| Vasculitis | 3 | 2011 | 47 | 0.220 |
Why?
|
| Heart Valve Diseases | 2 | 2022 | 174 | 0.220 |
Why?
|
| Vitamin K 2 | 1 | 2024 | 6 | 0.220 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 167 | 0.220 |
Why?
|
| Blood Platelets | 5 | 2016 | 318 | 0.220 |
Why?
|
| Immunosuppressive Agents | 6 | 2003 | 666 | 0.220 |
Why?
|
| Body Temperature | 1 | 2025 | 128 | 0.220 |
Why?
|
| Interleukin-18 | 2 | 2023 | 78 | 0.220 |
Why?
|
| Confidence Intervals | 5 | 2017 | 272 | 0.220 |
Why?
|
| Nonprescription Drugs | 2 | 2024 | 54 | 0.220 |
Why?
|
| Exercise Test | 4 | 2020 | 243 | 0.220 |
Why?
|
| Muscle Strength | 1 | 2025 | 82 | 0.220 |
Why?
|
| Allylamine | 1 | 2004 | 8 | 0.220 |
Why?
|
| 3T3-L1 Cells | 2 | 2015 | 53 | 0.220 |
Why?
|
| Muscles | 3 | 2016 | 222 | 0.220 |
Why?
|
| Life Expectancy | 1 | 2025 | 63 | 0.220 |
Why?
|
| Receptor for Advanced Glycation End Products | 5 | 2015 | 32 | 0.220 |
Why?
|
| Varicose Veins | 1 | 2024 | 28 | 0.220 |
Why?
|
| Protective Factors | 3 | 2021 | 93 | 0.220 |
Why?
|
| Benzodiazepines | 2 | 2017 | 110 | 0.220 |
Why?
|
| Superantigens | 1 | 2004 | 20 | 0.210 |
Why?
|
| Diet, Reducing | 5 | 2014 | 90 | 0.210 |
Why?
|
| Global Burden of Disease | 1 | 2024 | 33 | 0.210 |
Why?
|
| Estradiol | 2 | 2024 | 481 | 0.210 |
Why?
|
| Apolipoprotein A-V | 3 | 2013 | 23 | 0.210 |
Why?
|
| Inpatients | 1 | 2009 | 544 | 0.210 |
Why?
|
| Atrial Function, Left | 1 | 2024 | 36 | 0.210 |
Why?
|
| Fasting | 7 | 2013 | 303 | 0.210 |
Why?
|
| Periodontitis | 1 | 2024 | 22 | 0.210 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 295 | 0.210 |
Why?
|
| Recurrence | 5 | 2019 | 1487 | 0.210 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 53 | 0.210 |
Why?
|
| Thiophenes | 2 | 2014 | 68 | 0.210 |
Why?
|
| Interleukin-1 | 3 | 2021 | 131 | 0.210 |
Why?
|
| Gemfibrozil | 1 | 2003 | 4 | 0.210 |
Why?
|
| Databases, Factual | 6 | 2024 | 1224 | 0.210 |
Why?
|
| Fibrosis | 6 | 2022 | 421 | 0.210 |
Why?
|
| Myocardial Reperfusion | 5 | 2000 | 55 | 0.210 |
Why?
|
| Prescription Drugs | 2 | 2014 | 52 | 0.210 |
Why?
|
| Docosahexaenoic Acids | 2 | 2022 | 67 | 0.210 |
Why?
|
| Listeriosis | 1 | 2003 | 20 | 0.200 |
Why?
|
| Gene Knockdown Techniques | 1 | 2025 | 381 | 0.200 |
Why?
|
| Warfarin | 1 | 2024 | 123 | 0.200 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 129 | 0.200 |
Why?
|
| Cardiologists | 1 | 2023 | 26 | 0.200 |
Why?
|
| Epistasis, Genetic | 2 | 2014 | 98 | 0.200 |
Why?
|
| Amino Acids | 3 | 2018 | 620 | 0.200 |
Why?
|
| Fishes | 1 | 2023 | 33 | 0.200 |
Why?
|
| Models, Economic | 2 | 2025 | 57 | 0.200 |
Why?
|
| Quality of Health Care | 3 | 2016 | 411 | 0.200 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 910 | 0.200 |
Why?
|
| Apoptosis | 5 | 2015 | 1860 | 0.200 |
Why?
|
| Program Evaluation | 1 | 2005 | 443 | 0.200 |
Why?
|
| Clinical Competence | 4 | 2019 | 1058 | 0.200 |
Why?
|
| Cholesterol, VLDL | 4 | 2016 | 18 | 0.200 |
Why?
|
| Thinness | 2 | 2025 | 71 | 0.200 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 88 | 0.200 |
Why?
|
| Endpoint Determination | 2 | 2021 | 57 | 0.190 |
Why?
|
| Thrombosis | 2 | 2016 | 495 | 0.190 |
Why?
|
| Blood Flow Velocity | 3 | 2020 | 427 | 0.190 |
Why?
|
| Aortic Diseases | 2 | 2015 | 189 | 0.190 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2019 | 32 | 0.190 |
Why?
|
| Sepsis | 2 | 2026 | 501 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 204 | 0.190 |
Why?
|
| Electrocardiography | 9 | 2021 | 984 | 0.190 |
Why?
|
| Hepatitis | 1 | 2023 | 57 | 0.190 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2014 | 50 | 0.190 |
Why?
|
| Energy Intake | 2 | 2010 | 502 | 0.190 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 184 | 0.190 |
Why?
|
| Diet, Western | 2 | 2019 | 20 | 0.190 |
Why?
|
| Genetic Therapy | 2 | 2025 | 726 | 0.190 |
Why?
|
| Piperazines | 2 | 2014 | 273 | 0.190 |
Why?
|
| Proteins | 3 | 2004 | 1028 | 0.190 |
Why?
|
| Regression Analysis | 6 | 2021 | 773 | 0.190 |
Why?
|
| Albumins | 1 | 2022 | 92 | 0.190 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 12 | 0.190 |
Why?
|
| Blood Vessels | 3 | 2017 | 99 | 0.190 |
Why?
|
| Patient Care | 1 | 2023 | 99 | 0.190 |
Why?
|
| Hyperaldosteronism | 1 | 2022 | 18 | 0.190 |
Why?
|
| Physical Fitness | 4 | 2015 | 89 | 0.180 |
Why?
|
| Hypotension | 1 | 2024 | 185 | 0.180 |
Why?
|
| Antigens, CD | 5 | 2005 | 418 | 0.180 |
Why?
|
| Cerebrovascular Disorders | 3 | 2018 | 114 | 0.180 |
Why?
|
| Immunoassay | 4 | 2023 | 133 | 0.180 |
Why?
|
| Metabolome | 1 | 2025 | 326 | 0.180 |
Why?
|
| Creatinine | 5 | 2022 | 402 | 0.180 |
Why?
|
| Mississippi | 5 | 2024 | 35 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2024 | 273 | 0.180 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2017 | 371 | 0.180 |
Why?
|
| Frailty | 1 | 2024 | 141 | 0.180 |
Why?
|
| Neoplasms | 5 | 2026 | 2965 | 0.180 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2024 | 597 | 0.180 |
Why?
|
| Waist Circumference | 4 | 2014 | 95 | 0.180 |
Why?
|
| Thigh | 3 | 2022 | 52 | 0.180 |
Why?
|
| Spleen | 2 | 2018 | 257 | 0.180 |
Why?
|
| Self Medication | 1 | 2021 | 21 | 0.180 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 316 | 0.180 |
Why?
|
| Health Status Indicators | 2 | 2015 | 124 | 0.180 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 29 | 0.180 |
Why?
|
| Neutrophil Infiltration | 2 | 2002 | 65 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 283 | 0.180 |
Why?
|
| Osteocalcin | 1 | 2021 | 45 | 0.180 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.170 |
Why?
|
| Open Reading Frames | 1 | 2021 | 200 | 0.170 |
Why?
|
| Drug Interactions | 3 | 2011 | 241 | 0.170 |
Why?
|
| Graft Rejection | 5 | 2005 | 562 | 0.170 |
Why?
|
| Aldosterone | 2 | 2022 | 58 | 0.170 |
Why?
|
| Stress, Mechanical | 3 | 2016 | 179 | 0.170 |
Why?
|
| Contrast Media | 4 | 2019 | 492 | 0.170 |
Why?
|
| HLA-DRB1 Chains | 1 | 2021 | 47 | 0.170 |
Why?
|
| Reference Values | 6 | 2017 | 692 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 40 | 0.170 |
Why?
|
| Health Status | 3 | 2025 | 388 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2025 | 1093 | 0.170 |
Why?
|
| Corn Oil | 1 | 2020 | 10 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2022 | 51 | 0.170 |
Why?
|
| Nutrition Policy | 1 | 2021 | 91 | 0.170 |
Why?
|
| Exercise Therapy | 3 | 2015 | 175 | 0.170 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 55 | 0.170 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.170 |
Why?
|
| Propensity Score | 3 | 2012 | 266 | 0.170 |
Why?
|
| Obesity, Abdominal | 3 | 2020 | 41 | 0.170 |
Why?
|
| ABO Blood-Group System | 2 | 2011 | 61 | 0.170 |
Why?
|
| Phospholipases A2 | 3 | 2011 | 30 | 0.170 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 421 | 0.160 |
Why?
|
| Aortic Valve | 1 | 2024 | 460 | 0.160 |
Why?
|
| Canada | 2 | 2018 | 328 | 0.160 |
Why?
|
| Budgets | 1 | 2020 | 16 | 0.160 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 48 | 0.160 |
Why?
|
| Cardiovascular System | 1 | 2021 | 103 | 0.160 |
Why?
|
| Aorta | 3 | 2017 | 530 | 0.160 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 2 | 2016 | 43 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 2 | 2021 | 590 | 0.160 |
Why?
|
| Receptors, Prostaglandin | 3 | 2010 | 12 | 0.160 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 19 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 204 | 0.160 |
Why?
|
| Chromosomes, Human, X | 1 | 2021 | 155 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 75 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2020 | 48 | 0.160 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 683 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 105 | 0.160 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 95 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 33 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2020 | 109 | 0.160 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 195 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 139 | 0.160 |
Why?
|
| Serum Albumin | 2 | 2018 | 110 | 0.160 |
Why?
|
| Benzaldehydes | 2 | 2011 | 13 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 354 | 0.160 |
Why?
|
| Socioeconomic Factors | 5 | 2024 | 895 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 59 | 0.160 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 205 | 0.160 |
Why?
|
| Sialic Acids | 1 | 1999 | 17 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 31 | 0.160 |
Why?
|
| Preventive Medicine | 1 | 2019 | 18 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 193 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 771 | 0.150 |
Why?
|
| Diabetic Neuropathies | 1 | 2020 | 56 | 0.150 |
Why?
|
| Curriculum | 4 | 2019 | 785 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2000 | 57 | 0.150 |
Why?
|
| Perfusion | 2 | 2023 | 211 | 0.150 |
Why?
|
| Oximes | 2 | 2011 | 55 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2020 | 499 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 59 | 0.150 |
Why?
|
| Amlodipine | 1 | 2019 | 21 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2021 | 157 | 0.150 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2019 | 283 | 0.150 |
Why?
|
| Lisinopril | 1 | 2019 | 27 | 0.150 |
Why?
|
| CD11a Antigen | 4 | 2013 | 11 | 0.150 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.150 |
Why?
|
| Pulse Wave Analysis | 4 | 2025 | 53 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 25 | 0.150 |
Why?
|
| Adiposity | 3 | 2015 | 207 | 0.150 |
Why?
|
| Metoprolol | 1 | 2019 | 21 | 0.150 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 18 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2025 | 97 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2018 | 7 | 0.150 |
Why?
|
| Algorithms | 8 | 2016 | 1686 | 0.150 |
Why?
|
| Pneumococcal Infections | 1 | 2001 | 279 | 0.150 |
Why?
|
| Anti-Obesity Agents | 2 | 2010 | 46 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 59 | 0.150 |
Why?
|
| Interferon-gamma | 3 | 2021 | 542 | 0.150 |
Why?
|
| Patient Preference | 1 | 2020 | 146 | 0.150 |
Why?
|
| Carboxylic Acids | 1 | 2018 | 25 | 0.140 |
Why?
|
| Placebo Effect | 3 | 2016 | 20 | 0.140 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2013 | 260 | 0.140 |
Why?
|
| von Willebrand Factor | 4 | 2017 | 192 | 0.140 |
Why?
|
| Cell Differentiation | 4 | 2008 | 1951 | 0.140 |
Why?
|
| Transaminases | 1 | 2018 | 36 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 5 | 2019 | 300 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 181 | 0.140 |
Why?
|
| Walking | 1 | 2020 | 234 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 173 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 207 | 0.140 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2022 | 114 | 0.140 |
Why?
|
| CD47 Antigen | 1 | 2018 | 11 | 0.140 |
Why?
|
| Chromosome Deletion | 2 | 2000 | 652 | 0.140 |
Why?
|
| Tunica Media | 3 | 2010 | 15 | 0.140 |
Why?
|
| Hypotension, Orthostatic | 1 | 2018 | 20 | 0.140 |
Why?
|
| Biological Products | 1 | 2020 | 143 | 0.140 |
Why?
|
| Genetics, Population | 2 | 2021 | 185 | 0.140 |
Why?
|
| Chromosome Aberrations | 2 | 2005 | 577 | 0.140 |
Why?
|
| Ankle Brachial Index | 3 | 2020 | 41 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2013 | 49 | 0.140 |
Why?
|
| Solubility | 4 | 2014 | 118 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 359 | 0.140 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2014 | 49 | 0.140 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 146 | 0.140 |
Why?
|
| Research Design | 5 | 2016 | 723 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2023 | 231 | 0.140 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 118 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| X-Ray Microtomography | 2 | 2015 | 101 | 0.140 |
Why?
|
| Cell Line | 6 | 2015 | 2607 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2019 | 118 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2015 | 83 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 481 | 0.140 |
Why?
|
| Genome | 1 | 2020 | 473 | 0.140 |
Why?
|
| Posture | 1 | 2018 | 136 | 0.130 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 119 | 0.130 |
Why?
|
| Health Promotion | 1 | 2021 | 408 | 0.130 |
Why?
|
| Education | 1 | 2018 | 113 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 22 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 116 | 0.130 |
Why?
|
| Blood Specimen Collection | 2 | 2015 | 47 | 0.130 |
Why?
|
| Metagenomics | 1 | 2018 | 111 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 165 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 371 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2019 | 322 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 126 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 98 | 0.130 |
Why?
|
| Early Diagnosis | 3 | 2016 | 192 | 0.130 |
Why?
|
| Integrins | 3 | 2008 | 90 | 0.130 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 1319 | 0.130 |
Why?
|
| Receptors, CCR2 | 1 | 2017 | 24 | 0.130 |
Why?
|
| Phylogeny | 1 | 2019 | 712 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 226 | 0.130 |
Why?
|
| Machine Learning | 1 | 2021 | 375 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 635 | 0.130 |
Why?
|
| Fibric Acids | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tablets | 3 | 2008 | 38 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2019 | 49 | 0.130 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 191 | 0.130 |
Why?
|
| PPAR gamma | 1 | 2017 | 86 | 0.130 |
Why?
|
| Lipid Droplets | 1 | 2017 | 51 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2017 | 493 | 0.130 |
Why?
|
| Genetic Counseling | 1 | 2018 | 238 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 328 | 0.130 |
Why?
|
| Systole | 4 | 2019 | 197 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 155 | 0.120 |
Why?
|
| Thiazolidinediones | 2 | 2017 | 79 | 0.120 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 10 | 0.120 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 39 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2019 | 1522 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.120 |
Why?
|
| Alanine Transaminase | 2 | 2014 | 156 | 0.120 |
Why?
|
| Femoral Vein | 1 | 2016 | 48 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 20 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 491 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 209 | 0.120 |
Why?
|
| Brain | 5 | 2023 | 3247 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2019 | 267 | 0.120 |
Why?
|
| Sex Distribution | 4 | 2024 | 321 | 0.120 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 61 | 0.120 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 236 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 904 | 0.120 |
Why?
|
| beta 2-Microglobulin | 2 | 2014 | 36 | 0.120 |
Why?
|
| HIV Infections | 2 | 2022 | 2042 | 0.120 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 10 | 0.120 |
Why?
|
| Lipocalins | 2 | 2014 | 32 | 0.120 |
Why?
|
| Inservice Training | 1 | 2016 | 55 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 237 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2014 | 45 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 2018 | 168 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 227 | 0.110 |
Why?
|
| Internal Medicine | 2 | 2018 | 124 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1612 | 0.110 |
Why?
|
| Phospholipids | 2 | 2014 | 103 | 0.110 |
Why?
|
| Claudins | 1 | 2015 | 29 | 0.110 |
Why?
|
| Triazines | 1 | 2015 | 33 | 0.110 |
Why?
|
| Safety | 1 | 2016 | 216 | 0.110 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 63 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2016 | 181 | 0.110 |
Why?
|
| Behavior Therapy | 2 | 2014 | 272 | 0.110 |
Why?
|
| Heart Rate | 1 | 2018 | 580 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2014 | 614 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 404 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 125 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1610 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 79 | 0.110 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 548 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2021 | 1457 | 0.110 |
Why?
|
| Blood Donors | 1 | 2014 | 56 | 0.110 |
Why?
|
| Gene Expression | 6 | 2013 | 1503 | 0.110 |
Why?
|
| Chromosome Mapping | 3 | 2019 | 1069 | 0.110 |
Why?
|
| Subtilisins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Glucose Tolerance Test | 4 | 2021 | 200 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 290 | 0.110 |
Why?
|
| Dietary Fiber | 1 | 2014 | 78 | 0.110 |
Why?
|
| Occupations | 1 | 2014 | 19 | 0.110 |
Why?
|
| Histocompatibility Testing | 1 | 1994 | 109 | 0.100 |
Why?
|
| Osteonectin | 1 | 2013 | 5 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2025 | 126 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 241 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 57 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 236 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2014 | 230 | 0.100 |
Why?
|
| Foundations | 1 | 2013 | 23 | 0.100 |
Why?
|
| Absorption | 1 | 2013 | 50 | 0.100 |
Why?
|
| Sitosterols | 1 | 2013 | 10 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 83 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 246 | 0.100 |
Why?
|
| Athletes | 1 | 2014 | 72 | 0.100 |
Why?
|
| Panniculitis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 26 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 217 | 0.100 |
Why?
|
| Age of Onset | 3 | 2025 | 631 | 0.100 |
Why?
|
| Umbilical Veins | 2 | 2006 | 64 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2013 | 16 | 0.100 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 281 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1841 | 0.100 |
Why?
|
| Patient Education as Topic | 3 | 2021 | 466 | 0.100 |
Why?
|
| Family Practice | 2 | 2011 | 88 | 0.100 |
Why?
|
| Phantoms, Imaging | 2 | 2011 | 149 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 86 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 234 | 0.100 |
Why?
|
| HEK293 Cells | 3 | 2021 | 811 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 91 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 2 | 2026 | 236 | 0.100 |
Why?
|
| Drug Approval | 1 | 2013 | 46 | 0.100 |
Why?
|
| Internationality | 2 | 2024 | 130 | 0.100 |
Why?
|
| Mice, Obese | 2 | 2013 | 73 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 397 | 0.100 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1261 | 0.100 |
Why?
|
| Neck | 1 | 2014 | 145 | 0.100 |
Why?
|
| Pharmacogenomic Testing | 2 | 2024 | 46 | 0.100 |
Why?
|
| Linkage Disequilibrium | 4 | 2019 | 318 | 0.100 |
Why?
|
| Tangier Disease | 1 | 2012 | 6 | 0.100 |
Why?
|
| Musculoskeletal Diseases | 2 | 2003 | 56 | 0.100 |
Why?
|
| HLA Antigens | 1 | 1994 | 230 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 158 | 0.100 |
Why?
|
| Renin | 2 | 2023 | 76 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 157 | 0.090 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 3616 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 303 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 505 | 0.090 |
Why?
|
| 3T3 Cells | 3 | 2005 | 121 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 174 | 0.090 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 18 | 0.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 645 | 0.090 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 17 | 0.090 |
Why?
|
| Models, Biological | 3 | 2014 | 1396 | 0.090 |
Why?
|
| Renal Dialysis | 2 | 2010 | 952 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 111 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2013 | 155 | 0.090 |
Why?
|
| Standard of Care | 1 | 2013 | 135 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 333 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 260 | 0.090 |
Why?
|
| Nanomedicine | 1 | 2012 | 27 | 0.090 |
Why?
|
| Maryland | 3 | 2017 | 39 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 173 | 0.090 |
Why?
|
| North Carolina | 3 | 2017 | 65 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8604 | 0.090 |
Why?
|
| Base Sequence | 8 | 2011 | 2783 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2016 | 239 | 0.090 |
Why?
|
| Minnesota | 3 | 2017 | 181 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2009 | 1489 | 0.090 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2011 | 9 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 215 | 0.090 |
Why?
|
| Colestipol | 2 | 2004 | 6 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 824 | 0.090 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 38 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 1990 | 139 | 0.080 |
Why?
|
| Necrosis | 1 | 2011 | 195 | 0.080 |
Why?
|
| Polysomnography | 3 | 2019 | 155 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2015 | 932 | 0.080 |
Why?
|
| Smoking Cessation | 2 | 2025 | 190 | 0.080 |
Why?
|
| Diet, Fat-Restricted | 2 | 2011 | 37 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 152 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 168 | 0.080 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 138 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2024 | 1239 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 26 | 0.080 |
Why?
|
| Motor Activity | 2 | 2015 | 507 | 0.080 |
Why?
|
| Heart Atria | 2 | 2024 | 338 | 0.080 |
Why?
|
| Chagas Disease | 1 | 2014 | 314 | 0.080 |
Why?
|
| Molecular Sequence Annotation | 2 | 2021 | 152 | 0.080 |
Why?
|
| Blotting, Northern | 5 | 2003 | 236 | 0.080 |
Why?
|
| Health Services Research | 1 | 2011 | 178 | 0.080 |
Why?
|
| Sirolimus | 2 | 2002 | 231 | 0.080 |
Why?
|
| Protein Binding | 4 | 2017 | 1712 | 0.080 |
Why?
|
| Glycation End Products, Advanced | 3 | 2018 | 25 | 0.080 |
Why?
|
| Independent Living | 2 | 2024 | 66 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 124 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 620 | 0.080 |
Why?
|
| Duffy Blood-Group System | 1 | 2009 | 9 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 62 | 0.080 |
Why?
|
| Aryldialkylphosphatase | 2 | 2007 | 9 | 0.080 |
Why?
|
| Community-Based Participatory Research | 3 | 2018 | 63 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2003 | 130 | 0.080 |
Why?
|
| Age Distribution | 2 | 2018 | 429 | 0.080 |
Why?
|
| Cyclosporins | 1 | 1989 | 14 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2009 | 64 | 0.080 |
Why?
|
| Hemoglobins | 2 | 2024 | 314 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 481 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 153 | 0.080 |
Why?
|
| Markov Chains | 2 | 2025 | 100 | 0.080 |
Why?
|
| Chemotactic Factors | 2 | 2007 | 16 | 0.080 |
Why?
|
| Quinazolinones | 3 | 2016 | 6 | 0.070 |
Why?
|
| Diastole | 2 | 2020 | 179 | 0.070 |
Why?
|
| Chemokines | 1 | 2009 | 127 | 0.070 |
Why?
|
| Endocrinology | 1 | 2011 | 128 | 0.070 |
Why?
|
| Glycoproteins | 2 | 2024 | 349 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 1989 | 116 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 650 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1990 | 138 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 206 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 235 | 0.070 |
Why?
|
| Chymases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 10 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 105 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2008 | 14 | 0.070 |
Why?
|
| Piperidines | 1 | 2010 | 231 | 0.070 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 360 | 0.070 |
Why?
|
| Blood Component Removal | 2 | 2000 | 35 | 0.070 |
Why?
|
| Cloning, Molecular | 5 | 2005 | 787 | 0.070 |
Why?
|
| Morbidity | 3 | 2014 | 261 | 0.070 |
Why?
|
| Equipment Design | 3 | 2019 | 557 | 0.070 |
Why?
|
| Educational Status | 3 | 2017 | 281 | 0.070 |
Why?
|
| Oncogene Protein v-cbl | 1 | 2008 | 1 | 0.070 |
Why?
|
| Peritonitis | 3 | 2017 | 75 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2008 | 60 | 0.070 |
Why?
|
| Remission Induction | 2 | 2016 | 309 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 36 | 0.070 |
Why?
|
| Apolipoprotein B-100 | 3 | 2016 | 36 | 0.070 |
Why?
|
| Fibrinolytic Agents | 2 | 2023 | 200 | 0.070 |
Why?
|
| India | 1 | 2008 | 245 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2004 | 59 | 0.070 |
Why?
|
| Erythrocytes | 3 | 2016 | 192 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 146 | 0.070 |
Why?
|
| Alcoholic Beverages | 1 | 2007 | 17 | 0.070 |
Why?
|
| 14-3-3 Proteins | 1 | 2008 | 57 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2010 | 216 | 0.070 |
Why?
|
| Assisted Circulation | 1 | 1987 | 22 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 432 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2015 | 726 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2010 | 359 | 0.070 |
Why?
|
| Iceland | 1 | 2007 | 12 | 0.070 |
Why?
|
| Drug Utilization | 2 | 2020 | 164 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 1999 | 137 | 0.070 |
Why?
|
| Cadherins | 1 | 2008 | 178 | 0.070 |
Why?
|
| Appetite Depressants | 1 | 2007 | 23 | 0.070 |
Why?
|
| Naphthalenes | 1 | 1987 | 38 | 0.070 |
Why?
|
| Xanthomatosis | 1 | 1987 | 8 | 0.070 |
Why?
|
| Glutamate Decarboxylase | 1 | 2007 | 43 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2008 | 186 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2006 | 18 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 989 | 0.060 |
Why?
|
| Weight Gain | 3 | 2017 | 384 | 0.060 |
Why?
|
| Memory, Episodic | 2 | 2017 | 29 | 0.060 |
Why?
|
| Brain Diseases, Metabolic | 1 | 1987 | 16 | 0.060 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 31 | 0.060 |
Why?
|
| Iron Overload | 1 | 2007 | 18 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2007 | 93 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2020 | 169 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 128 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 671 | 0.060 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2006 | 27 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2022 | 15066 | 0.060 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 572 | 0.060 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 185 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 1997 | 366 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2018 | 1217 | 0.060 |
Why?
|
| Chemokine CCL11 | 1 | 2005 | 12 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 81 | 0.060 |
Why?
|
| Restriction Mapping | 3 | 1994 | 171 | 0.060 |
Why?
|
| Fibronectins | 1 | 2005 | 99 | 0.060 |
Why?
|
| Particulate Matter | 1 | 2026 | 92 | 0.060 |
Why?
|
| Microspheres | 1 | 2005 | 68 | 0.060 |
Why?
|
| Hand Strength | 1 | 2025 | 59 | 0.060 |
Why?
|
| Chylomicrons | 1 | 2025 | 10 | 0.060 |
Why?
|
| Australia | 1 | 2025 | 176 | 0.060 |
Why?
|
| Arthritis, Experimental | 1 | 2005 | 20 | 0.060 |
Why?
|
| Health Priorities | 1 | 2005 | 42 | 0.060 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2016 | 69 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2123 | 0.060 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2004 | 5 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 519 | 0.060 |
Why?
|
| Critical Illness | 2 | 2020 | 616 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 2004 | 2566 | 0.050 |
Why?
|
| Ionomycin | 1 | 2004 | 15 | 0.050 |
Why?
|
| Endarterectomy, Carotid | 2 | 2015 | 76 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2013 | 955 | 0.050 |
Why?
|
| Dogs | 7 | 2000 | 632 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 998 | 0.050 |
Why?
|
| Massachusetts | 1 | 2024 | 118 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2021 | 175 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2021 | 350 | 0.050 |
Why?
|
| Walking Speed | 1 | 2024 | 18 | 0.050 |
Why?
|
| RNA Splicing Factors | 1 | 2024 | 52 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2005 | 207 | 0.050 |
Why?
|
| Knowledge Bases | 1 | 2024 | 40 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2024 | 35 | 0.050 |
Why?
|
| Enterotoxins | 1 | 2004 | 77 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 228 | 0.050 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2024 | 14 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2014 | 1746 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2007 | 466 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2024 | 50 | 0.050 |
Why?
|
| Ezetimibe, Simvastatin Drug Combination | 3 | 2009 | 3 | 0.050 |
Why?
|
| Leukocyte Rolling | 1 | 2003 | 4 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 252 | 0.050 |
Why?
|
| Teaching | 1 | 2005 | 196 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2024 | 61 | 0.050 |
Why?
|
| CpG Islands | 1 | 2025 | 341 | 0.050 |
Why?
|
| Anthropometry | 2 | 2014 | 190 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2024 | 83 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2021 | 165 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2024 | 73 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 40 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2003 | 30 | 0.050 |
Why?
|
| Bradycardia | 1 | 2024 | 57 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2003 | 87 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 107 | 0.050 |
Why?
|
| Nausea | 1 | 2003 | 83 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 95 | 0.050 |
Why?
|
| RNA | 2 | 2005 | 530 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2024 | 128 | 0.050 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 237 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2004 | 337 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 266 | 0.050 |
Why?
|
| Radiography | 3 | 2017 | 762 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1008 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2004 | 2442 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 276 | 0.050 |
Why?
|
| Knee Joint | 2 | 2017 | 174 | 0.050 |
Why?
|
| Vitamin B Complex | 1 | 2003 | 38 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 51 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 1020 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2024 | 167 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2024 | 157 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2003 | 291 | 0.050 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2002 | 8 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 61 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 145 | 0.050 |
Why?
|
| Plasminogen | 2 | 2014 | 7 | 0.050 |
Why?
|
| Length of Stay | 1 | 2009 | 1400 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 214 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 111 | 0.050 |
Why?
|
| Body Composition | 1 | 2005 | 550 | 0.050 |
Why?
|
| Patient Discharge | 2 | 2018 | 512 | 0.050 |
Why?
|
| Mineral Oil | 1 | 2022 | 5 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 149 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2023 | 78 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 62 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2002 | 39 | 0.050 |
Why?
|
| Premenopause | 1 | 2022 | 38 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 375 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2023 | 241 | 0.050 |
Why?
|
| Poloxamer | 1 | 2022 | 14 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2022 | 11 | 0.050 |
Why?
|
| Calibration | 2 | 2015 | 95 | 0.050 |
Why?
|
| Proteinuria | 1 | 2022 | 106 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2020 | 432 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2024 | 195 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 234 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2000 | 185 | 0.050 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2024 | 140 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2022 | 79 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 45 | 0.050 |
Why?
|
| Anoctamins | 1 | 2021 | 13 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 344 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 67 | 0.040 |
Why?
|
| Software Validation | 1 | 2021 | 9 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 139 | 0.040 |
Why?
|
| Caloric Restriction | 2 | 2013 | 106 | 0.040 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 109 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 460 | 0.040 |
Why?
|
| Hybrid Cells | 3 | 2008 | 78 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 2001 | 29 | 0.040 |
Why?
|
| Diarrhea | 1 | 2003 | 312 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 256 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 72 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 60 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2021 | 14 | 0.040 |
Why?
|
| Probability | 3 | 2010 | 310 | 0.040 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2001 | 41 | 0.040 |
Why?
|
| Waist-Hip Ratio | 2 | 2012 | 54 | 0.040 |
Why?
|
| Meningoencephalitis | 1 | 2001 | 20 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 329 | 0.040 |
Why?
|
| Esterases | 1 | 2001 | 12 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2021 | 103 | 0.040 |
Why?
|
| Child | 5 | 2024 | 26332 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 2012 | 803 | 0.040 |
Why?
|
| Receptors, Leptin | 1 | 2021 | 41 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 93 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2021 | 118 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2001 | 144 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2021 | 61 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2021 | 58 | 0.040 |
Why?
|
| Capsules | 1 | 2000 | 22 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2000 | 13 | 0.040 |
Why?
|
| Kinetics | 3 | 2000 | 1105 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Peroxidase | 1 | 2001 | 64 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2003 | 411 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2002 | 314 | 0.040 |
Why?
|
| Chlamydophila Infections | 1 | 2000 | 3 | 0.040 |
Why?
|
| Otitis Media | 1 | 2001 | 89 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2000 | 10 | 0.040 |
Why?
|
| fas Receptor | 1 | 2000 | 43 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2020 | 42 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 72 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 117 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2021 | 158 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 28 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 243 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2026 | 1916 | 0.040 |
Why?
|
| Anemia | 1 | 2024 | 356 | 0.040 |
Why?
|
| NADPH Dehydrogenase | 1 | 2000 | 7 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 16 | 0.040 |
Why?
|
| Meningitis, Bacterial | 1 | 2001 | 98 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 382 | 0.040 |
Why?
|
| Men's Health | 1 | 2020 | 22 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 50 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 136 | 0.040 |
Why?
|
| Hypothalamic Diseases | 1 | 2020 | 40 | 0.040 |
Why?
|
| Diethylamines | 2 | 2011 | 4 | 0.040 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 54 | 0.040 |
Why?
|
| Thymus Gland | 2 | 1991 | 102 | 0.040 |
Why?
|
| Binding Sites | 2 | 2000 | 1204 | 0.040 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1999 | 6 | 0.040 |
Why?
|
| Interphase | 1 | 1999 | 35 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 83 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2014 | 812 | 0.040 |
Why?
|
| Homeostasis | 1 | 2024 | 714 | 0.040 |
Why?
|
| Carbohydrate Conformation | 1 | 1999 | 15 | 0.040 |
Why?
|
| Sialyltransferases | 1 | 1999 | 7 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 99 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 109 | 0.040 |
Why?
|
| Rheology | 1 | 1999 | 25 | 0.040 |
Why?
|
| Sulfides | 2 | 2011 | 28 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 161 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 328 | 0.040 |
Why?
|
| Lectins | 1 | 1999 | 50 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 7 | 0.040 |
Why?
|
| Ureteral Obstruction | 1 | 2000 | 104 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2021 | 239 | 0.040 |
Why?
|
| Pyrimidinones | 2 | 2011 | 64 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 319 | 0.040 |
Why?
|
| Exons | 3 | 2014 | 769 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 117 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 1999 | 2 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 271 | 0.040 |
Why?
|
| Biphenyl Compounds | 2 | 2011 | 75 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 162 | 0.040 |
Why?
|
| Family | 1 | 2022 | 593 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2014 | 469 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 95 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 1027 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 504 | 0.040 |
Why?
|
| Placebos | 2 | 2011 | 227 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 299 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 52 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 72 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 166 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Carbon-Carbon Lyases | 1 | 2018 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 482 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 134 | 0.040 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2018 | 6 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 39 | 0.040 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2020 | 1018 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2483 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2017 | 400 | 0.040 |
Why?
|
| Talin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2018 | 31 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2001 | 389 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 1987 | 999 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 245 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 230 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 363 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 394 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 261 | 0.040 |
Why?
|
| Immunoturbidimetry | 1 | 2018 | 1 | 0.030 |
Why?
|
| Poverty | 1 | 2022 | 456 | 0.030 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2012 | 16 | 0.030 |
Why?
|
| Health Facilities | 1 | 2018 | 68 | 0.030 |
Why?
|
| Microcirculation | 1 | 1998 | 107 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2000 | 310 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2020 | 291 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2019 | 366 | 0.030 |
Why?
|
| Interleukin-12 | 2 | 2013 | 124 | 0.030 |
Why?
|
| Phagocytes | 1 | 1997 | 25 | 0.030 |
Why?
|
| Preliminary Data | 1 | 2017 | 9 | 0.030 |
Why?
|
| Androgens | 1 | 2020 | 272 | 0.030 |
Why?
|
| Sequestering Agents | 1 | 2017 | 1 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2020 | 291 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2000 | 430 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 46 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 175 | 0.030 |
Why?
|
| England | 1 | 2017 | 58 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 131 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 752 | 0.030 |
Why?
|
| Factor VIII | 1 | 2017 | 51 | 0.030 |
Why?
|
| Quebec | 1 | 2017 | 5 | 0.030 |
Why?
|
| Genome, Human | 2 | 2017 | 1338 | 0.030 |
Why?
|
| Vitamin E | 1 | 2017 | 63 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 51 | 0.030 |
Why?
|
| Thioglycolates | 1 | 1997 | 12 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 424 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 1997 | 23 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 353 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1997 | 28 | 0.030 |
Why?
|
| Income | 1 | 2017 | 135 | 0.030 |
Why?
|
| France | 1 | 2017 | 90 | 0.030 |
Why?
|
| Bacteremia | 1 | 2001 | 428 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2000 | 520 | 0.030 |
Why?
|
| Adenoviridae | 1 | 1999 | 586 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 1398 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 709 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2000 | 359 | 0.030 |
Why?
|
| Phosphorus | 1 | 2017 | 61 | 0.030 |
Why?
|
| Platelet Count | 1 | 2017 | 140 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1997 | 194 | 0.030 |
Why?
|
| Endocytosis | 1 | 2017 | 129 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 30 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1997 | 104 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 872 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2017 | 91 | 0.030 |
Why?
|
| Magnesium | 1 | 2017 | 121 | 0.030 |
Why?
|
| Myalgia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 136 | 0.030 |
Why?
|
| Vascular Diseases | 2 | 2010 | 155 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2017 | 86 | 0.030 |
Why?
|
| Cricetulus | 1 | 2016 | 88 | 0.030 |
Why?
|
| CHO Cells | 1 | 2016 | 149 | 0.030 |
Why?
|
| Blood Volume | 1 | 2016 | 71 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 532 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2368 | 0.030 |
Why?
|
| C-Peptide | 1 | 2016 | 107 | 0.030 |
Why?
|
| Corrosion Casting | 1 | 1995 | 2 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 50 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 1995 | 11 | 0.030 |
Why?
|
| Sports | 2 | 2009 | 64 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 31 | 0.030 |
Why?
|
| California | 1 | 2016 | 128 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Introns | 1 | 2017 | 288 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 205 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 680 | 0.030 |
Why?
|
| Death Certificates | 1 | 2015 | 10 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 440 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 1999 | 907 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2013 | 810 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 287 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 261 | 0.030 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1995 | 4 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 74 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1995 | 27 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 72 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 417 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 447 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 48 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2018 | 332 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 16 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 176 | 0.030 |
Why?
|
| Integrin alpha4beta1 | 2 | 2008 | 26 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 297 | 0.030 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 128 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2015 | 9 | 0.030 |
Why?
|
| Vitamin B 6 | 2 | 2006 | 9 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 365 | 0.030 |
Why?
|
| Phospholipases | 1 | 1994 | 9 | 0.030 |
Why?
|
| Myocarditis | 2 | 1994 | 132 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1131 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 228 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 328 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 154 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 324 | 0.030 |
Why?
|
| Lymph | 3 | 2000 | 7 | 0.030 |
Why?
|
| Life Tables | 1 | 1994 | 27 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 38 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1994 | 37 | 0.030 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 20 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2014 | 62 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2018 | 406 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 64 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 140 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 410 | 0.030 |
Why?
|
| Endocardium | 1 | 1994 | 47 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 272 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1165 | 0.030 |
Why?
|
| Genetic Code | 1 | 2014 | 22 | 0.030 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2014 | 25 | 0.030 |
Why?
|
| Proinsulin | 1 | 2013 | 13 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 244 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 113 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 216 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2014 | 63 | 0.030 |
Why?
|
| Cricetinae | 2 | 2005 | 367 | 0.030 |
Why?
|
| Dermatitis, Contact | 1 | 1993 | 6 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 94 | 0.030 |
Why?
|
| Cattle | 2 | 2006 | 521 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 239 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 20 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 6 | 0.030 |
Why?
|
| Fatty Acid Desaturases | 1 | 2013 | 13 | 0.030 |
Why?
|
| Rats | 2 | 2002 | 3462 | 0.030 |
Why?
|
| Random Allocation | 2 | 1996 | 423 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 108 | 0.020 |
Why?
|
| Venules | 2 | 2003 | 28 | 0.020 |
Why?
|
| Endosonography | 1 | 2013 | 79 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 2012 | 31 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 551 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1992 | 30 | 0.020 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 58 | 0.020 |
Why?
|
| Reoperation | 1 | 1996 | 844 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 169 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 341 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 149 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 563 | 0.020 |
Why?
|
| Stem Cells | 1 | 1997 | 713 | 0.020 |
Why?
|
| Corneal Stroma | 1 | 2012 | 75 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 150 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 20 | 0.020 |
Why?
|
| Gene Targeting | 2 | 2003 | 171 | 0.020 |
Why?
|
| Radio Waves | 1 | 2011 | 9 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 1991 | 120 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 42 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 67 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 137 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2015 | 558 | 0.020 |
Why?
|
| Autoradiography | 1 | 1991 | 65 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 39 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 120 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 1991 | 50 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 208 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1991 | 155 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2010 | 15 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2010 | 11 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 282 | 0.020 |
Why?
|
| Biopsy | 1 | 1994 | 1252 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 299 | 0.020 |
Why?
|
| Syndrome | 1 | 1993 | 1170 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 294 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2010 | 53 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2011 | 123 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2012 | 247 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 252 | 0.020 |
Why?
|
| Integrin alpha4 | 2 | 2002 | 12 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 103 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 98 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2010 | 130 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2009 | 36 | 0.020 |
Why?
|
| Glycolysis | 1 | 2010 | 171 | 0.020 |
Why?
|
| Pregnancy | 2 | 2013 | 7577 | 0.020 |
Why?
|
| Antibodies, Blocking | 2 | 2002 | 57 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 1235 | 0.020 |
Why?
|
| Metabolic Equivalent | 1 | 2009 | 6 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 147 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2009 | 75 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 218 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 39 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 391 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 117 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 344 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2008 | 25 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1714 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2002 | 589 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 1630 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 242 | 0.020 |
Why?
|
| Interleukin-4 | 2 | 2000 | 145 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1990 | 472 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 5 | 0.020 |
Why?
|
| Leishmania major | 1 | 2008 | 27 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1988 | 73 | 0.020 |
Why?
|
| Epinephrine | 1 | 2009 | 150 | 0.020 |
Why?
|
| Complement Factor H | 1 | 2008 | 24 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 54 | 0.020 |
Why?
|
| Caspase 10 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Collagen | 1 | 2009 | 289 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 99 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1812 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 97 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1989 | 177 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 1987 | 19 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 59 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1987 | 132 | 0.020 |
Why?
|
| Tendons | 1 | 1987 | 32 | 0.020 |
Why?
|
| Angiography | 1 | 1987 | 188 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2008 | 166 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2013 | 810 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1987 | 335 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 609 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1419 | 0.020 |
Why?
|
| Umbilical Cord | 1 | 2005 | 61 | 0.010 |
Why?
|
| Outpatients | 1 | 2007 | 266 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2008 | 231 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2008 | 363 | 0.010 |
Why?
|
| Allergens | 1 | 2008 | 356 | 0.010 |
Why?
|
| Stents | 1 | 2011 | 780 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 436 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2004 | 32 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2005 | 253 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 96 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2008 | 401 | 0.010 |
Why?
|
| Epitopes | 1 | 2005 | 432 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2005 | 313 | 0.010 |
Why?
|
| Pyridoxal Phosphate | 1 | 2003 | 12 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 486 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2004 | 173 | 0.010 |
Why?
|
| Hemostasis | 1 | 2003 | 74 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 626 | 0.010 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 2003 | 15 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2004 | 191 | 0.010 |
Why?
|
| Ion Transport | 1 | 2003 | 48 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 2003 | 36 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 121 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 196 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 694 | 0.010 |
Why?
|
| Causality | 1 | 2003 | 92 | 0.010 |
Why?
|
| Lung | 2 | 2006 | 1571 | 0.010 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2002 | 31 | 0.010 |
Why?
|
| Integrin alphaXbeta2 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2002 | 18 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2004 | 519 | 0.010 |
Why?
|
| Hemorheology | 1 | 2002 | 25 | 0.010 |
Why?
|
| Abdominal Muscles | 1 | 2002 | 28 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 372 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 694 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2003 | 241 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 334 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 275 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2002 | 99 | 0.010 |
Why?
|
| Lipopolysaccharides | 2 | 1993 | 302 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 900 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2006 | 724 | 0.010 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2000 | 3 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2000 | 5 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 288 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2000 | 9 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 21 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 26 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2000 | 41 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2000 | 36 | 0.010 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2000 | 23 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 76 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2000 | 77 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1993 | 426 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 76 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2000 | 96 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 3708 | 0.010 |
Why?
|
| Ligation | 1 | 2000 | 137 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 53 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 157 | 0.010 |
Why?
|
| Azepines | 1 | 2000 | 62 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2000 | 108 | 0.010 |
Why?
|
| Food-Drug Interactions | 1 | 1999 | 10 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1998 | 17 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1998 | 43 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1998 | 33 | 0.010 |
Why?
|
| Osteopontin | 1 | 1998 | 51 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2000 | 148 | 0.010 |
Why?
|
| Mast Cells | 1 | 1998 | 65 | 0.010 |
Why?
|
| Histamine Release | 1 | 1997 | 10 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 36 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 772 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1997 | 74 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1996 | 31 | 0.010 |
Why?
|
| Veins | 1 | 1997 | 99 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1996 | 318 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1999 | 819 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 943 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 960 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 23 | 0.010 |
Why?
|
| Software | 1 | 1999 | 756 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1993 | 84 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 308 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 152 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 255 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 452 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 213 | 0.010 |
Why?
|